Price (delayed)
$0.2097
Market cap
$13.53M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.59
Enterprise value
$2.88M
GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate
There are no recent dividends present for GLYC.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.